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Abstract

SCHIZOPHRENIA CANDIDATE GENES STUDY
By Grace Hyeiwon Lee, M.S.
A thesis submitted in partial fulfillment of the requirements for the degree of Masters at
Virginia Commonwealth University.
Virginia Commonwealth University, 2009
Major Director: Xiangning Chen
Associate Professor, School of Medicine

Schizophrenia is a debilitating disorder caused by the interaction of genetic and
environmental factors. In this study, we identified candidate genes and single nucleotide
polymorphisms from two genome-wide association studies, GAIN and CATIE. Nine
SNPs representing four candidate genes were selected for replication studies with our
Irish samples: Irish Case-Control Study of Schizophrenia (ICCSS), the Irish Study of
High-Density Schizophrenia Families (ISHDSF), and the Irish Trio Study of
Schizophrenia (ITRIO). In the ITRIO sample, rs4704591 (CMYA5 gene) showed
nominal significance (p = 0.0447947). Combining ICCSS, ISHDSF, and ITRIO samples
for rs4704591 increased sample size and power and yielded a p-value of 0.00388. This
marker remained significant after Bonferroni correction for 9 markers genotyped in this
study. CMYA5 gene binds to dysbindin protein in muscle. The dysbindin gene may
influence glutamatergic neurotransmission, which has been suspected of being a
mechanism by which the pathophysiology of schizophrenia is manifest. Our data suggest
CMYA5 gene may be associated with schizophrenia in Caucasian subjects.
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CHAPTER 1: INTRODUCTION
1.1. Schizophrenia
1.1.1 Epidemiology & Significance of Schizophrenia
Schizophrenia (SZ) is a chronic, severely debilitating brain disorder with a
lifetime risk of approximately 1%. The National Institute of Mental Health (NIMH)
reports the number of Americans affected by SZ to be approximately 2.4 million (NIMH,
2009). Factors such as the gravity of physical and emotional suffering undergone by
patients and caretakers are important in determining the significance of a disorder. In
addition, the economic burden caused by a disorder is also noteworthy. A study (Wu et
al., 2005) reported the overall U.S. 2002 cost of SZ was estimated to be $62.7 billion. Of
the total, excess direct health care cost contributed $22.7 billion ($7.0 billion outpatient,
$5.0 billion drugs, $2.8 billion inpatient, and $8.0 billion long-term care). The total
indirect excess costs contributed $32.4 billion, and the total direct non-health care excess
costs contributed $7.6 billion. Only 10% to 15% of people with SZ are estimated to be
able to maintain full-time employment, which led to the direct excess cost due to
unemployment being the largest component of overall SZ excess costs. There is no
consensus on geographic and temporal variations in incidence rates. Some claim SZ
occurs in diverse populations over the world at comparable rates (Jablensky et al., 1992),
and that its incidence rate has remained similar over the past two centuries (Jablensky &
Kalaydjieva, 2003). Others, concluded up to fivefold variation is seen in world-wide
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incidence of SZ (McGrath et al., 2004). Regardless, the prevalence of SZ in the U.S. and
the world establishes SZ as a vital area of research efforts.
SZ typically manifests in late adolescence or in early adult life. Females tend to
have a later onset than males, and females also tend to have a milder form of the disorder
with a better outcome than males. McGrath et al. (2004) reported the occurrence of SZ to
be higher among males with a mean rate ratio of 1.4. SZ is also known to prevail to a
greater extent in cities. Poverty, poor nutrition, inadequate healthcare and education are
thought to attribute to the risk-increasing effects of urbanization. A certain migrant
groups also show a higher incidence of SZ especially if they are relatively isolated with
their own ethnic group in a small minority. Some of the well-replicated findings are with
African-Caribbean migrants in the United Kingdom and Norwegians in the United States
(Murray et al., 2008).
1.1.2. Symptoms of Schizophrenia
Schizophrenia is a multi-dimensional disorder with variable phenotype
expressions (Figure 1). Such heterogeneity is in part determined by the age of onset, and
patients’ predominant symptoms may change as the disease progresses. Nothing the
various materializations of the disorder, SZ is generally characterized by symptoms of
psychosis such as hallucinations and delusions, and they are a major component of the
diagnostic criteria for SZ in the Diagnostic and Statistical Manual of Mental Disorders,
4th edition (DSM-IV) (Figure 2). Hallucinations are generally auditory sensation in which
patients believe they hear abusive or derogatory comments, although somatic or visual
sensations manifest in some cases as well. Delusions, or false beliefs, range from
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believing oneself to be under surveillance as a part of religious or political conspiracy to
believing one’s thoughts to be controlled by an evil will. Most delusions are of a paranoid
nature, and some are religious, grandiose, or sexual. Hallucinations and delusions are
termed positive symptoms, and they become more resistant to antipsychotic drug
treatments with each succeeding schizophrenic episode. SZ patients also show derailment
of thought and incoherent, illogical speech (Murray et al., 2008).
Negative symptoms of SZ include: social withdrawal, apathy, loss of motivation,
slowness of thought and action, and poverty of thought and speech. As suggested by
manifestations, negative symptoms accompany cognitive impairment especially in
memory, attention and executive functions. Negative symptoms are prominent in chronic
patients, and they accumulate gradually. These symptoms are harder to measure than
positive symptoms, but they tend to be more persistent and are related to worse
prognostics for patients (Murray et al., 2008). SZ patients also experience mood
symptoms which make them feel hopeless and suicidal. In fact, research indicates that at
least 5-13% of schizophrenia patients die by suicide, with the higher end of the range
being the more accurate estimate (Pompili et al., 2007).
1.1.3. Etiology of Schizophrenia
Schizophrenia is caused by the interaction of genetic and environmental factors
(Figure 3), and the genetic contribution is regarded as the most important of the known
etiologic factors. The heritability of SZ liability is estimated to be up to 85%. The main
sources of evidence for the genetic predisposition are studies of relatives, twin studies,
and adoption studies (Murray et al., 2008). In a study with all patients with SZ on the
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Roscommon County Case Register in Ireland, Kendler et al. (1993) found the lifetime
risk of SZ for the first-degree relative of SZ patients to be 6.5% and that for the relatives
of control subjects to be 0.5%. Other studies also report a higher incidence of SZ with
relatives of SZ patients. According to NIMH, although SZ occurs in about 1 percent of
the general population, it occurs at around 10 percent of the people with a first-degree
relative with the disorder. NIMH also states people with a second-degree relative with SZ
are also more likely than the general population to develop SZ (NIMH, 2009). Twin
studies have further established genetic contributions to SZ. A monozygotic twin of a SZ
patient has 41 to 65 percent chance of developing the disorder. The concordance rate is 0
to 28 percent for dizygotic twins (Cardino & Gottesman, 2000). Such studies firmly
establish the role of genetics in SZ, but it is important to note that although SZ is
mediated by genetics, it is not determined by it. In addition to the genetic factor, various
environmental risk factors have been suggested. Although environmental risk factors
operate throughout the life course, some believe the risk factors in action early in life –
before or shortly after birth—cause abnormalities in the nervous system formation
making an individual vulnerable to psychosis. These early inflictions include prenatal
exposure to viruses, malnutrition in the womb, pregnancy complications such as bleeding,
diabetes, and pre-eclampsia, complications of delivery such as uterine atony, emergency
C section and asphyxia, and abnormal fetal growth and development such as low birth
weight, and small head circumference. Neurodevelopmental abnormalities caused by
early environmental insults may be aggravated and may lead to brain dysfunction by
additional environmental factors in childhood or adolescence. Such factors include social
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isolation, child abuse, and use of cannabis or other street drugs (Murray et al., 2008). In
sum, genetic factors may predispose an individual to SZ, and such individual may
become schizophrenic upon encountering environmental stress factors at various stages
of his life.
1.1.3.1 Genetic Etiology of Schizophrenia
According to Kendler et al. (1993), what is transmitted through genes include
predisposition to minor cognitive deficits, poor psychosocial functioning, suspiciousness
and oddness and also to psychotic illness, schizotypal personality and paranoid
personality disorder. In addition, not only the liability to SZ but also the specific clinical
character of the disorder has been attributed to familial influence (Fanous & Kendler,
2005). The major focus of the genetics research on SZ has been on identifying the genes
that are associated with SZ. The genetics research on SZ has come a long way since its
embarkation in 1916, and more than 2000 association studies involving 500 genes have
been reported for either positive or negative associations with SZ (Sun et al. 2008).
Although the genetic etiology and pathogenesis of SZ remains largely elusive to date,
linkage studies suggest that no one gene exists that increases the risk of SZ by more than
three-fold, meaning that there may be a number of susceptibility genes (Murray et al.,
2008). In fact, multiple genes and alleles in various combinations may contribute to the
genetic background of the disorder, with a proportion of the transmitted genotypes
remaining clinically unexpressed (Gottesman & Bertelsen, 1989).
Based on the polygenic multifactorial model of schizophrenia, many putative
susceptibility genes have been found, including: DRD3, 5HT2a, DISC1, DISC2, COMT,
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ProDH, RGS4, DTNBP1 (dysbindin), NRG1 (neuregulin 1), G72 and DAAO. The list of
possible susceptibility genes is ever expanding, but the results of the studies showing
positive associations with SZ are not well-replicated (Murray et al., 2008). It should also
be considered that not all identified candidate genes may be susceptibility genes, meaning
that studies suggest some genes may influence clinical features of SZ without changing
the susceptibility to SZ. Such “modifier genes” have been demonstrated to be present in
other diseases as well. Another challenge of unraveling the genetic etiology of SZ stems
from possible genetic mechanisms that may alter the expression of correctly identified
genes such as epistatsis, pleiotropy, imprinting, genetic heterogeneity, and phenocopies
(Fanous & Kendler, 2005). Detailed discussion of all such genetic models of SZ is
beyond the scope of this paper, but copy number variation (CNV) in particular, is an area
of investigation for its undisputed pathogenic role in SZ (Williams et al., 2008).
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The Complexity of Symptoms in Schizophrenia

Positive Symptoms
• Delusions
• Hallucinations
• Disorganized speech
• Catatonia

Cognitive Symptoms
• Attention
• Memory
• Executive functions

Negative Symptoms
• Apathy
• Social withdrawal
• Loss of
motivation

Mood Symptom
• Suicidality
• Hopelessness
• Dysphoria

Figure 1. The Complexity of Symptoms in Schizophrenia. Schizophrenia is a
multi-dimensional disorder with variable phenotype expressions. It is believed that
a variety of molecular pathways involving many different susceptibility genes
contributes to this heterogeneity.
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1. At least two of A (only one of A required if delusions are
bizarre or hallucinations consist of running commentary
or discussing voices)
2. Continuous signs of disturbance for at least 6 months
with at least 1 month of acute phase symptoms (A)
3. Exclusions: the disorder must not be attributable to
schizoaffective or mood disorder with psychotic features,
the direct effects of a substance or a general medical condition
4. Social/occupational dysfunction (below the level of
expected functioning)
A
•
•
•
•
•

Delusions
Hallucinations
Disorganized speech
Grossly disorganized or catatonic behavior
Negative symptoms

Figure 2. Diagnostic criteria for schizophrenia from DSM-IV-TR.

9

Etiologic Pathway of Schizophrenia

Genetic Predisposition
Early environmental risk factors
• Prenatal viral infection
• Pregnancy stress/factors
9 Malnutrition in womb
9 Delivery complications
9 Abnormal fetal growth

Neurodevelopmental
Abnormalities
Later environmental risk factors
• Social isolation/stress
• Child abuse
• Marijuana/Cannabis use

Further brain dysfunction
& Schizophrenia
Psychosis

Neurodegeneration &
Schizophrenia
Figure 3. Etiologic Pathway of Schizophrenia. Schizophrenia is caused by the
interaction of genetic and environmental factors.
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1.2. Genome-wide Association Studies
1.2.1. What is a Genome-wide Association Study?
A genome-wide association study, GWAS, emerged as the completion of the
Human Genome Project (2003) and the International HapMap Project (2005). These
projects provided computerized databases containing the reference human genome
sequence, a map of human genetic variation, and new technologies that enable analyses
of whole-genome samples for genetic variations (NHGRI, 2009).
The GWAS and association studies in general are conducted using two groups of
participants: people with the disease being studied, and similar people without the disease.
Once the participants’ blood or cells are obtained, each person’s genome is purified and it
is surveyed for selected markers of genetic variation called single nucleotide
polymorphisms, or SNPs. If a certain genetic variation is observed significantly more
frequently in people with the disease, it is said to be associated with the disease. The
associated variants have their value in locating the regions of the human genome in which
disease-causing problems reside (National Human Genome Research Institute [NHGRI],
2009).
What distinguishes the GWAS from other association studies is that the GWAS
allows finding of genetic variations associated with particular diseases by rapidly
scanning markers across the genome – the complete set of DNA –, of many individuals.
This allows researchers to sample 500,000 or more SNPs from each subject, enabling
them to capture variations across the genome at uniform distances between SNPs. The

11

ability to scan the entire genome, in turn, makes the GWAS a hypothesis-free study, in
which candidates identified are more objective.
In the early stages, genetic association studies identified genes responsible for
numerous monogenic disorders such as CFTR (cystic fibrosis), Huntingtin (Huntington’s
disease), BRCA1 (breast and ovarian cancer) and so forth. However, such approach to
identify genes in multigenic diseases – diseases caused by the combined effect of
multiple polymorphisms in a number of genes – has faced more challenges (Barnes,
2007). The GWAS is considered to have the potential to yield substantial insights into
various disorders including psychiatric disorders. Its power to detect small effects without
specific knowledge of pathogenesis has especially been useful for researching the
genetics of complex disorders (Williams, Owen & O’Donovan, 2009).
1.2.2. Genome-wide Association Studies of Schizophrenia
Association studies in SZ have evolved in parallel with GWAS technology, and
there have been a number of findings based on positional approaches with compelling
evidence. Such findings are likely to include true susceptibility genes, but evidence has
not been unequivocal, especially in terms of specific alleles or haplotypes. There have
been six published GWASs of schizophrenia up to date, of which three have been based
on DNA pooling and one has been limited to non-synonymous SNPs (Williams et al.,
2009). These studies reported a number of significant associations with various genes
including CSF2RA and SHOX (Mah et al., 2006), ZNF804A (O’Donovan et al., 2008),
and reelin (Shiftman et al., 2008). And yet, no findings from the published GWAS studies
were able to report a locus that reaches genome-wide levels of significance in any single
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or combined study until recently (Dudbridge & Gusnanto, 2008). In 2009, however, The
International Schizophrenia Consortium (2009) reported the major histocompatibility
complex on chromosome 6 to have reached GWAS significance.
Williams et al. (2009) states that more robust results for other disorders have
come from GWAS applied to large patient and control samples and also from follow-up
analyses in even larger samples. Such approaches are being applied to SZ in recent years
and have yielded some promising results. The success of the future SZ GWAS studies
depends largely on assembly of large, well-phenotyped patient samples, effective
collaboration and sharing of patient resources, and the ability to handle and analyze
increasingly large and complex data sets.
1.3. Hypothesis of the Study
GWAS has the potential to identify genes involved schizophrenia. Although most
published data sets did not identify candidate genes in these individual studies, these
datasets contain valuable information that can be extracted to identify promising
candidates. We hypothesized that each individual study of GWAS had useful information
and that by combining multiple datasets we could increase our probability of successfully
identifying promising candidate genes. To test this hypothesis, we selected all markers
with p-values <= 0.05 from both GAIN and CATIE studies, and matched them against
each other. We further refined our selection using linkage disequilibrium data from
neighboring markers, the function of the markers and relevance to schizophrenia in
PubMed databases. Using these processes, we selected a total of 9 markers in 4 genes and
tested their association in our independent Irish samples.
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CHAPTER 2: MATERIALS & METHODS
2.1. Subjects
All samples used were obtained and organized by other researchers prior to the
current study.
2.1.1. The Irish Study of High-Density Schizophrenia Families (ISHDSF)
sample
The ISHDSF sample was collected in Northern Ireland, the United Kingdom, and
the Republic of Ireland. Phenotypes were assessed using DSM-III-R. The diagnoses were
formed into a hierarchy of 10 categories reflecting the probable genetic relationship of
these syndromes to classic SZ. This hierarchy consisted of three definitions of affection:
1) Narrow – categories D1 and D2, or “core schizophrenia” – schizophrenia, pooroutcome schizoaffective disorder and simple schizophrenia; 2) Intermediate – categories
D1-D5, or a narrow definition of the schizophrenia spectrum, adding to the narrow
definition schizotypal personality disorder, schizophreniform disorder, delusional
disorder, atypical psychosis and good-outcome schizoaffective disorder; 3) Broad –
categories D1-D8, including all disorders that significantly aggregated in relatives of
schizophrenic probands in the Roscommon Family Study (Kendler et al., 1993) and
adding to the intermediate definition mood incongruent and mood congruent psychotic
affective illness, and paranoid, avoidant and schizoid personality disorder. The final
inclusion criteria for pedigrees in the ISHDSF sample required two or more first, second,
or third-degree relatives with a diagnosis of D1-D5, one or more of whom had a D1-D2
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diagnosis. The sample contained 273 pedigrees and about 1350 subjects had DNA sample
for genotyping. Of them, 515 were diagnosed with the narrow definition (351 males and
164 females), 634 were diagnosed with the intermediate definition, and 686 were
diagnosed with the broad definition. Of these, 522 were used as cases in this study, and
869 were used as controls. Detailed descriptions of the sample were published previously
(Kendler et al., 2000).
2.1.2. The Irish Case-Control Study of Schizophrenia (ICCSS) sample
The ICCSS sample was collected in Northern Ireland, the United Kingdom and
the Republic of Ireland. In this study, we used 657 (436 males and 221 females) affected
subjects and 411 (233 males and 178 females) control subjects. The affected subjects
were selected from in-patient and out-patient psychiatric facilities in the Republic of
Ireland and Northern Ireland. Subjects were eligible for inclusion if they had a diagnosis
of schizophrenia or poor-outcome schizoaffective disorder by DSM-III-R criteria, and the
diagnosis was confirmed by a blind expert diagnostic review. Control subjects, selected
from several sources, including blood donation centers, were included if they denied a
lifetime history of schizophrenia. However, the fact that control subjects were not
screened by clinicians is a potential weakness in the study design. Both case and control
subjects were included only if they reported all four grandparents as being born in Ireland
or the United Kingdom. Family history (FH), based on the family-history research
diagnostic criteria (Endicott, Andreasen & Spitzer, 1978), was assessed by clinical
interview of probands and their relatives. Subjects having a first or second-degree relative
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diagnosed with schizophrenia were classified as FH positive. In the ICCSS sample, there
were 117 subjects (71 males and 46 females) classified with positive FH of schizophrenia.
2.1.3. The Irish Trio Study of Schizophrenia (ITRIO) sample
The ITRIO samples were collected in the same period as the ICCSS sample. The
inclusion criteria and symptom ascertainments were identical to those of ICCSS samples.
ITRIO samples included probands and their fraternal and maternal parents. Of the 187
families from whom samples were collected, 26 families had two affected subjects; two
families had three affected subjects; and the remainder had a single affected subject. In
addition, there were 29 subjects who had another first or second-degree relative
diagnosed with schizophrenia. DNA samples from a total number of 216 affected
subjects and 372 unaffected subjects were used for the current study.
2.2. Genome-wide Association Study Datasets
2.2.1. The Genetic Association Information Network Study
The Genetic Association Information Network (GAIN) is a public-private
partnership funding genome-wide association studies established by the Foundation for
the National Institute of Health. The GAIN’s initial study to genotype existing research
studies in six major common diseases was completed in 2007, and the resulting data are
being deposited in a database that is available to the research community upon approved
request. The network’s initial efforts focused on Attention Deficit Hyperactivity Disorder,
diabetic neuropathy in type I diabetes, major depression, psoriasis, schizophrenia, and
bipolar disorder (Foundation for the National Institute of Health, 2008).
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For the current study, the GAIN study data was obtained. The data included
information for 906600 markers for 4505 individual samples. Only the Caucasian subset
of the GAIN’s samples was used for this study. There were 2601 subjects (1172 cases,
1378 controls, 51 missing phenotype; 1485 males and 1115 females) in this subset. Along
with the CATIE study data, the GAIN study data was used extensively in the current
study as a method of selecting candidate genes and markers.
2.2.2. The Clinical Antipsychotic Trials of Intervention Effectiveness Study
The Clinical Antipsychotic Trials of Intervention Effectiveness Study, funded by
the National Institutes of Health’s National Institute of Mental Health, is a clinical trial
comparing the effectiveness of older (first available in the 1950s) and newer (available
since the 1990s) antipsychotic medications that are used to treat schizophrenia (National
Institute of Mental Health, 2009). The study’s data is available to the research community
upon approved request. The CATIE study’s 1492 participants (741 cases and 751
controls) included SZ patients across the United States being treated in a variety of
settings. For the current study, the Caucasian subset of the CATIE’s samples was used.
There were 492 cases and 523 controls (771 males and 244 females) in this subset,
totaling 1015 subjects. The CATIE study data obtained included information for 495172
markers. The CATIE study dataset was used in the current study for selecting candidate
genes and markers.
Participants for the CATIE study were eligible to be included in the study if all of
the following criteria were met: 1) 18-65 years old; 2) DSM-IV diagnosis of
schizophrenia; 3) adequate capacity to consent. They were excluded in the following
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cases: 1) intolerance of failure to respond to one of the treatments; 2) diagnoses of
schizoaffective disorder, mental retardation, pervasive developmental disorder, delirium,
dementia, amnesia; 3) first episode of schizophrenia; 4) women currently pregnant or
breast-feeding; 5) have a serious and unstable medical condition (Lieberman et al., 2005).
The details of ascertainment and demographics of the CATIE subjects have been
published by Lieberman et al. in 2005.
2.3. Management of GWAS Data
For the purpose of managing the contents of the GAIN and CATIE datasets to fit
the needs of the current study, a genomic analysis software, PLINK (v. 1.05) (Purcell,
2007), was used. Using PLINK, each of the two GWAS datasets were compartmentalized
into two different datasets according to the subject’s race (white or black). This was done
as ISHDSF, ICCSS, and ITRIO samples are all of Caucasian descent. The CATIE study
data yielded 1015 white subjects and 477 non-white subjects; the GAIN study data
yielded 2601 white subjects and 1904 black subjects. The CATIE study included samples
whose races are neither Caucasian nor black, and thus, the term “non-white” was used.
2.4. Selection of Genes of Interest
In this study, an approach was taken in which a range of candidate genetic
markers were pre-selected if they met the following criteria: 1) markers are included in
both the GAIN study dataset and also in the CATIE study dataset, and 2) allelic p-values
are less than 0.05 in both datasets. Allelic p-values were calculated from only Caucasian
samples in both GAIN and CATIE datasets. From this process, 1229 markers covering
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315 genes were pre-selected. Out of 1229 markers, 682 markers were not a part of known
genes; they were precluded from further analyses.
The preceding part of the study confided in subjectivity, as no systematic scoring
strategy was used. The following were considered to choose candidate genes from the
315 pre-selected genes:
1) Current knowledge regarding location of gene expression & functions of the gene:
Upon literature search of individual genes, genes with known biological functions in the
nervous system were given more significant consideration for biological plausibility.
2) Physical proximity to other likely candidate genes: Significant consideration was given
also to genes that are physically close to other pre-select genes.
3) Number of markers from a particular gene that are included the pre-selected markers:
Genes that contain numerous (4 or more) markers from the pre-select marker list were
placed in a higher priority list.
4) Gene region covered by the markers in the pre-selected list (i.e. intron, UTR, near
gene, etc.): A special interest was given to genes that contain markers with missense
mutations. Genes whose pre-select markers are confined to the untranslated region (UTR)
or near-gene regions were given relatively less consideration.
5) Previously reported association with schizophrenia or other mental disorders: Genes
that have been studied related to schizophrenia or other mental disorders –bipolar
disorder, Alzheimer’s disease, and Parkinson’s disease in particular- were given a special
consideration.
2.5. Marker Selection and Genotyping
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A total of nine markers from four genes that had shown significant associations (p
< 0.05) with SZ from GAIN and CATIE white samples were selected. These markers
covered the following genes: Protein Tyrosine Phosphate Non-receptor Type 21
(PTPN21), Echinoderm Microtubule-Associated Protein-Like 5 (EML5),
Cardiomyopathy Associated 5 (CMYA5), and Nitric Oxide Synthase 1 Adaptor Protein
(NOS1AP). All markers contained in the GWAS datasets from each selected candidate
gene were extracted using PLINK (v. 1.05) (Purcell, 2007). PLINK (v.1.05) was also
used to analyze the associations of these markers in samples from the GWAS datasets.
Analyses were done via linear regression with the CATIE dataset, and via allelic
associations for the GAIN dataset. Using the linear regression with the CATIE dataset
allowed for covariates to be accounted for. The linkage disequilibrium (LD) for GAIN
and CATIE datasets was examined for each candidate gene using the HAPLOVIEW
program. Multiple factors were taken into consideration in electing SNPs for individual
candidate genes. These include the number of markers showing nominal significance, the
LD of these markers and their frequencies, and the location and nature of the
polymorphisms (i.e. whether these markers change an amino acid, splicing site,
transcription factor binding site etc).
All markers were typed using the TaqMan method. In the TaqMan method, the
TaqMan probe consists of two types of fluorophores, which are the fluorescent parts or
reporter proteins. While the probe is attached or unattached to the template DNA and
before the polymerase acts, the quencher fluorophore reduces the fluorescence from the
reporter fluorophore. After the denaturation of template DNA reaction cools, the TaqMan
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probe binds to its specific piece of the template DNA, and the primers anneal to the DNA.
Taq polymerase adds nucleotides to remove the TaqMan probe from the template DNA,
which separates the quencher (at 3’-end) from the reporter (at 5’-end), and the reporter
emits its energy which is quantified using a computer (Livak, 1999). SNPs typed by this
method were either validated assays or custom designed assays developed by Applied
BioSystems Corporation (Foster City, CA). All markers were genotyped for the ICCSS
and ISHDSF samples, and only the markers for the CMYA5 gene were genotyped
additionally for the ITRIO sample. All genotypes were scored using a semi-automated
Excel template developed in our lab (van den Oorde, et al., 2003). All markers typed
were checked for deviation from the Hardy-Weinberg Equilibrium (HWE) and
Mendelian errors by the PEDSTATS program (Wigginton et al., 2005).
2.6. Statistical Analyses
The ISHDSF sample was analyzed using the pedigree disequilibrium test (PDT)
(Martin et al., 2000) as implemented in the UNPHASED program (version 2.4,
PDTPHASE module) (Dudbridge, 2003) for single marker associations. Single marker
association tests compare frequencies of particular alleles, or genotypes, in affected and
unaffected subjects. In these analyses, both vertical and horizontal transmissions were
included. The p-values reported were based on weighing all families equally (the ave
option in the program). For the ICCSS sample, the new version (v. 3.1) of the
UNPHASED program (Dudbridge, 2008) was used to analyze single marker associations.
For the ITRIO sample, since all samples were from nuclear families with no unaffected
siblings, transmission disequilibrium test (TDT) as implemented in the TDTPHASE
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module of the UNPHASED program was used. In the combined analyses of discovery
samples (GAIN & CATIE), single marker associations were obtained using the
linear/logistic regression p-value platform of the PLINK (v.1.05) program. For the
combined analyses of replication samples (ICCSS + ISHDSF + ITRIO), single marker
associations were performed using the UNPHASED program (v. 3.10).
Odds ratio and confidence interval were computed for all samples using version
3.1 of the UNPHASED program, as version 2.4 did not provide the information needed
for the computation in the ISHDSF and ITRIO samples. In all samples, the odds ratio
compared case to control allele frequencies. The test statistic is χ2 = [(a/(a+c))/(b/(b+d))],
where a = number of major alleles present in cases, c = number of minor alleles present
in cases, b = number of major alleles present in controls and d = number of minor alleles
present in controls. The odds ratio was constructed as (a/c)/(b/d).
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CHAPTER 3: RESULTS
3.1. Selected Candidate Genes
3.1.1. Protein Tyrosine Phosphate Non-receptor Type 21 (PTPN21) Gene
Seven markers from the PTPN21 gene on Chromosome 14q31.3 were present in
the pre-selected marker list (Table 1). PTPN21 and EML5 genes, also one of the selected
candidate genes, are a relatively small distance away in chromosomal position. The two
genes are a 60 kb away, having ZC3H14 as the only gene between them (Figure 4).
PTPN21 and EML5 were the only genes aggregated in the same region of the genome
with 4 or more markers for each gene present in the pre-selected marker list. A number of
SZ studies to date have uncovered specific regions of the genome spanning multiple
genes to be liable for the disease. Such specific regions of the genome include 5q21-31
(Pimm et al., 2005; Petryshen et al., 2005; Chen et al., 2006; Chen et al., 2007), 22q12q13, 8p22-p21, 6p24-p22, 13q14-q32, and 6q21-q22 (Riley & Kendler, 2006). Thus, the
physical proximity of the two genes, PTPN21 and EML5, presented a possibility of
discovering a novel region of the genome implicated with SZ.
PTPN21 is a member of the protein tyrosine phosphatase (PTP) family. PTP
proteins are known to be signaling molecules regulating various cellular processes such
as cell growth, mitotic cycle, differentiation, and oncogenic transformation. PTPN21,
specifically, has been shown to interact with a member of Tec tyrosine kinase,
BMX/ETK. PTPN21 has also shown evidence for playing a role in liver regeneration and
spermatogenesis (Zeitlin et al., 2007). Although biological roles played by PTPN21
known to date do not appear to provide obvious links to SZ, many cellular processes that

23

PTP family of proteins regulate have been shown to be irregular in SZ. For instance,
McCurdy et al. (2006) reported significantly more mitosis in SZ patients compared to
controls. Their microarray data also suggested alterations to the cell cycle in SZ. This
suggests a possibility that PTPN21 may have an effect on the cell cycle in SZ.
3.1.2. Echinoderm Microtubule-Associated Protein-Like 5 (EML5) Gene
The EML5 gene, located on Chromosome 14q31.3, contained six markers in the
pre-selected marker list (Table 1). This gene has been shown to be expressed in the rat
brain, especially at high levels in the hippocampus, cerebellum, and olfactory bulb.
EML5 has homology to EMAP, the major microtubule-associated protein in dividing sea
urchin embryos. EML5 contains WD40 and HELP domains that have been suggested to
be involved in microtubule binding. It has been suggested that like other EMAP-like
proteins, EML5 plays a role in the regulation of cytoskeletal rearrangements during
neuronal development and in adult brain (O’Conner et al., 2004). The gene being
expressed in the brain made it a more attractive candidate gene. Also, studies have
implied involvement of other genes regulating cytoskeletal arrangements with SZ
(Hennah & Porteous, 2009; Kleppisch & Feil, 2009) which provides further evidence for
the relevance of EML5 to SZ. Along with EML5’s proximity to PTPN21, as discussed
above, its biological significance contributed to its potential to be a gene that may be
implicated with SZ.
3.1.3. Cardiomyopathy Associated 5 (CMYA5) Gene
The CMYA5 gene, located on Chromosome 5q14.1, contained three markers in
the pre-selected marker list (Table 1). The CMYA5 gene is a muscle-specific member of
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the TRIM superfamily. Studies have shown its expression in cardiac and skeletal muscle.
It is involved in protein kinase A signaling and vesicular trafficking. So far, the gene has
been reported in studies involving Duchenne muscular dystrophy and cardiac disease
(Sarparanta, 2008). CMYA5 was also shown to be a binding partner for dysbindin protein
in muscle, and it is intriguing to note that dysbindin, involved in the biogenesis of
lysosome-related organelles, has been receiving much attention as a key SZ susceptibility
factor (Benson, Tinsley, & Blake, 2004). The dysbindin gene may influence
glutamatergic neurotransmission, which has long been suspected of being a mechanism
by which the pathophysiology of SZ is manifest (Sodhi, Wood, & Meador-Woodruff,
2008). As previously identified SZ susceptibility genes have shown biological pathways
involving multiple genes to be engaged in pathogenic mechanisms of SZ, CMYA5 gene’s
relation to dysbindin gene offers a motive for further investigation of CMYA5 as a
candidate gene.
Out of the three markers of the CMYA5 gene in the pre-selected marker list, two
of them consisted of missense mutations. This is significant because the likely outcome
of proteins encoded with missense mutations can be expected to be non-functional. In
fact, such mutations are responsible for a number of diseases such as sickle-cell disease
and amyotrophic lateral sclerosis. In SZ research, a widely studied candidate gene DISC1
contains missense mutations that give rise to phenotypes in SZ (Millar et al., 2007). Out
of the 1229 total markers in the pre-selected marker list, there were 11 missense
mutations total. There were only two genes that contained 2 or more markers with
missense mutations, and they were PTPN21 and CMYA5. The prevalence of missense
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mutations in pre-selected markers presented a case for possible protein dysfunctions that
has an effect on SZ.
3.1.4. Nitric Oxide Synthase 1 Adaptor Protein (NOS1AP) Gene
The NOS1AP gene, located on Chromosome 1q22, contained six markers in the
pre-selected marker list (Table 1). This gene encodes a cytosolic protein that binds to the
signaling molecule, neuronal nitric oxide synthase (nNOS), which regulates neuronal
nitric-oxide (NO) synthesis (Jaffrey et al., 1998). Chromosome 1q22 is a locus initially
identified as of interest from linkage studies of SZ. Recent studies have implicated the
NOS1AP gene in susceptibility to SZ in various ethnic samples (Bruzustowicz et al.,
2004; Zheng et al., 2005; Xu et al., 2005). However, replication studies have been
inconsistent (Fang et al., 2008; Puri et al., 2006). After the completion of the current
study, more studies linking NOS1AP with SZ susceptibility were published; Kremeyer et
al. (2009) found eight SNPs in the NOS1AP gene to be statistically significant in SZ
samples from South America. Also, Wratten et al. (2009) found the A allele of
rs12742393 to be a risk allele associated with SZ via enhancing transcription factor
binding and gene expression. The presence of NOS1AP gene markers with significant pvalues in the pre-select marker list made the gene an appealing choice of a candidate gene
supported by previous findings on the gene’s association with SZ.
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Marker

Chr

rs2274736
rs2401751
rs1864744
rs7160647
rs10138002
rs10150311
rs11847417

14
14
14
14
14
14
14

Marker

Chr

rs10132509
rs17260415
rs10140896
rs12880096
rs7147796
rs7157149

14
14
14
14
14
14

Marker

Chr

rs6880680
rs3828611
rs10043986
rs4704591

5
5
5
5

Marker

Chr

rs1123217
rs4656349
rs1337062
rs1337061
rs4657150
rs164151

1
1
1
1
1
1

Location
(bp)
88008405
88016375
88020759
88043437
88046168
88046225
88046703

Gene
Region
MM
MM
Intron
Intron
Intron
Intron
intron

PTPN21
Polymorphism GAIN
p-value
G/A
0.00106
A/G
0.00084
C/G
0.00101
T/C
0.00106
A/G
0.00092
G/A
0.00133
A/G
0.00104

GAIN
MAF
0.354
0.354
0.354
0.318
0.318
0.317
0.318

CATIE
p-value
0.01705
0.01883
0.02501
0.03853
0.03834
0.04164
0.03618

Location
(bp)
88273534
88281726
88288291
88288568
88298322
88301598

Gene
Region
Intron
Intron
Intron
Intron
Intron
Intron

EML5
Polymorphism GAIN
p-value
T/C
0.0183
G/C
0.00650
G/C
0.00892
T/C
0.02032
C/G
0.03648
G/A
0.00812

GAIN
MAF
0.448
0.280
0.464
0.463
0.469
0.273

CATIE
p-value
0.02896
0.04058
0.02532
0.02744
0.01437
0.01

Location
(bp)
79058467
79070418
79131173
79139217

Location
(bp)
160307219
160316448
160329647
160329876
160368688
160605586

CMYA5
Gene
Polymorphism GAIN
Region
p-value
Intron
C/G
0.01146
MM
G/C
0.02248
MM
T/C
0.04148
UTR
G/C
0.00036

GAIN
MAF
0.075
0.058
0.135
0.385

CATIE
p-value
0.01209
0.01704
0.02514
0.03813

NOS1AP
Gene
Polymorph
Region
-ism
Intron
G/C
Intron
G/A
Intron
C/T
Intron
A/G
Intron
C/T
Near gene C/T

GAIN
MAF
0.030
0.295
0.298
0.299
0.349
0.153

CATIE
p-value
0.01887
0.01278
0.03275
0.0346
0.00914
0.01037

GAIN
p-value
0.00028
0.01439
0.01036
0.00064
0.02003
0.02792

Table 1. All pre-select SNPs (GAIN & CATIE p<0.05) on candidate genes. Denotation: MAF,
Minor allele frequency; MM, Missense Mutation; UTR, Untranslated region.
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Genomic Context of PTPN21 & EML5 Genes

Chromosome: 14; Location: 14q31.3

Bp: 88001875

Bp: 88647320

PTPN21

EML5

TTC8

LOC390501

ZC3H14

Figure 4. Genomic Context of PTPN21 & EML5 Genes. PTPN21 and EML5 genes are 60 kb away, having ZC3H14 as the only
gene between them.
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3.3. Linkage Disequilibrium Structures & Selected SNPs
Detailed descriptions of the final list of markers selected and genotyped are listed in
Table 3. The linkage disequilibrium (LD) structures spanning the candidate genes are indicated
by the pseudo-color matrix, with darker shades indicating strong LD between a pair of
chromosomal markers. Markers in strong LD are transmitted together on a chromosome, and
thus can be used as proxies when searching for markers associated with disease risk (Petryshen
et al., 2005).
3.3.1. PTPN21
From the GAIN study, 9 markers were included for PTPN21 with the p-value of less than
0.05. In the CATIE study data, 10 markers were included for PTPN21 with the same criteria.
One marker from the CATIE study was expelled as it did not meet the minimum HWE p-value
(HW p-value > 0.01). There were 7 common markers between the two datasets that meet all
requirements (Table 1). Out of the 7 common markers, there were 2 markers that cause missense
mutations and they were included in the replication study; rs2274736 and rs2401751. The LD
structure of the 7 common markers revealed that GAIN study (white samples only) grouped all 7
markers in one block, whereas the CATIE study grouped them into two separate blocks (Figure
5). Since the 2 missense mutation causing markers belong to only one of the two LD blocks in
CATIE, one additional marker was selected from the LD block from which no marker has been
chosen; rs10150311. Out of the 4 markers this LD block contained, rs10150311 was chosen as
the tag SNP from the HaploView program. In sum, rs2274736, rs2401751, and rs10150311 were
chosen to be tested for the PTPN21 gene (Table 3, Figure 10).
3.3.2. EML5
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From the GAIN study white samples, 7 markers were included for EML5 with the pvalue of less than 0.05. In the CATIE study data, 8 markers were included for EML5 with the
same criteria. There were 6 markers from each dataset that were in common with the other
(Table 1), and all of these markers were shown to be form a tight LD block (Figure 6). However,
out of the 6 markers, 4 did not meet the HWE cutoff (HW p-value > 0.01) for CATIE, and these
markers were omitted from the study. This yielded 2 markers to be tested for the EML5 gene;
rs17260415 and rs7147796 (Table 3, Figure 11).
3.3.3. CMYA5
Two of the three markers from the pre-select list of common significant markers between
GAIN (white sample) and CATIE were chosen for the study, since they cause missense
mutations (rs3828611 & rs10043986). The LD maps of all common markers between GAIN and
CATIE datasets, regardless of their p-values, are shown in Figure 7 and 8. Rs4704591 was later
added to the current study upon comparative analyses of all markers in the gene plus 20 KB
upstream and downstream sequences in the GAIN and CATIE datasets. Table 2 shows
rs4704591 as the marker with the lowest p-value from the combined analyses of GAIN and
CATIE Caucasian datasets. In sum, rs3828611, rs10043986, and rs4704591 were chosen to be
tested for the CMYA5 gene (Table 3, Figure 12).
3.3.4. NOS1AP
Using the HaploView program, a list of four tag SNPs were made for common markers
between GAIN (white sample) and CATIE. However, two of the markers did not meet the HWE
criteria for the CATIE study. Therefore, rs1123217 and rs1337062 were chosen to be tested.
However, the company from which the markers were ordered from failed to manufacture
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rs1337062. In sum, only rs1123217 was tested in the current study (Table 3, Figure 13). Figure 9
shows LD maps of NOS1AP gene.
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Marker
rs3087813
rs11960229
rs16877060
rs6870619
rs6880680
rs3828611
rs1991483
rs1428227
rs12655366
rs259124
rs259127
rs259129
rs259130
rs12657828
rs1129770
rs66682
rs3749683
rs10043986
rs7343
rs16877214
rs735639
rs259067
rs259066
rs259064
rs4704591
rs430866
rs17471700

GAIN Allelic
P-value
0.04322
0.16513
0.97432
0.01205
0.00942
0.01799
0.04335
0.35889
0.02697
0.30637
0.00633
0.00550
0.56299
0.80540
0.41612
0.16659
0.20457
0.04579
0.29541
0.17563
0.02712
0.27719
0.21252
0.04508
0.00036
0.07734
0.12049

CATIE Allelic
P-value
0.31680
0.28656
0.78186
0.06333
0.02118
0.06267
0.08867
0.25859
0.61408
0.57222
0.30154
0.40468
0.60695
0.00307
0.33013
0.65761
0.06374
0.00411
0.30116
0.09249
0.27799
0.31467
0.24477
0.55884
0.03813
0.55305
0.08197

GAIN & CATIE
Combined Allelic P-value
0.02482
0.54371
0.89937
0.00161
0.00068
0.00310
0.00904
0.18088
0.03383
0.25216
0.00445
0.00547
0.44294
0.06365
0.89374
0.16700
0.89035
0.00126
0.73649
0.77931
0.19888
0.14943
0.09726
0.04532
0.00004
0.06905
0.70503

Table 2. Comparative analyses of all markers of CMYA5 gene in GAIN & CATIE datasets.
rs4704591 showed the lowest p-value. P-values were computed using the UNPHASED program
and are slightly different from the p-values in Table 3, which were computed using the pLink
program.
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Marker Marker
ID
1
rs2274736

Gene
PTPN21

Polymorphism GAIN
MAF
G/A
0.354

GAIN
p-value
0.00106

2

rs2401751

PTPN21

A/G

0.354

0.00084

3

rs10150311 PTPN21

G/A

0.317

0.00133

4

rs17260415 EML5

G/C

0.280

0.00650

5

rs7147796

EML5

C/G

0.469

0.03648

6

rs3828611

CMYA5

G/C

0.058

0.02248

7

rs10043986 CMYA5

T/C

0.135

0.04148

8

rs4704591

CMYA5

C/G

0.386

0.00036

9

rs1123217

NOS1AP

G/C

0.030

0.00028

GAIN
OR
0.8385
[0.7455, 0.9431]
0.8256
[0.7335, 0.9292]
0.8341
[0.7389, 0.9416]
0.859
[0.757, 0.9747]
1.1179
[1, 1.2498]
1.3121
[1.0476, 1.6434]
0.8435
[0.7133, 0.9973]
0.813
[0.7255, 0.9111]
0.593
[0.4458, 0.7889]

MAF denotes minor allele frequency; OR denotes odds ratio.

Table 3: Final list of SNPs. Marker characteristics in GAIN & CATIE datasets.

CATIE
MAF
0.390

CATIE
p-value
0.01705

0.347

0.01883

0.371

0.04164

0.238

0.04058

0.367

0.01437

0.101

0.01704

0.091

0.02514

0.385

0.03812

0.124

0.01887

CATIE
OR
0.8368
[0.7222, 0.9696]
0.8157
[0.7013, 0.9487
0.8811
[0.7588, 1.0232]
0.8195
[0.692, 0.9705]
1.0302
[0.8866, 1.197]
1.4255
[0.9796, 2.074
0.6718
[0.5107, 0.8835]
0.8273
[0.6915, 0.9898]
0.8293
[0.6408, 1.073]
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LD Block Structures of Common Markers between GAIN & CATIE: PTPN21

Figure 5. LD Block Structures of Common Markers
between GAIN & CATIE: PTPN21

rs11847417

rs101503112

rs10138002

rs7160647

rs1864744

rs2401751

rs2274736

rs11847417

rs10150311

rs10138002

rs7160647

rs1864744

2) GAIN

rs2401751

rs2274736

1) CATIE
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LD Block Structures of Common Markers between GAIN & CATIE: EML5

Figure 6. LD Block Structures of Common Markers between GAIN & CATIE: EML5

rs7157149

rs7147796

rs12880096

rs10140896

rs17260415

rs7157149

rs7147796

rs12880096

rs10140896

rs17260415

rs10132509

rs10132509

2) GAIN

1) CATIE

35

LD Block Structures of Common Markers between GAIN & CATIE: CMYA5
1) CATIE

Figure 7. LD Block Structures of Common Markers between GAIN & CATIE: CMYA5 on CATIE
platform. Common markers throughout the CMYA5 gene regardless of their p-values are shown here.

Denotations:
1) rs3087813
2) rs11960229
3) rs16877060
4) rs6870619
5) rs6880680
6) rs3828611
7) rs1991483
8) rs1428227
9) rs12655366
10) rs259124
11) rs259127
12) rs259129
13) rs259130
14) rs12547828
15) rs1129770
16) rs66682
17) rs3749683
18) rs10043986
19) rs7343
20) rs16877214
21) rs735639
22) rs259067
23) rs259066
24) rs259053
25) rs4704591
26) rs430866
27) rs17471700
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LD Block Structures of Common Markers between GAIN & CATIE: CMYA5
2) GAIN

Figure 8. LD Block Structures of Common Markers between GAIN & CATIE: CMYA5 on GAIN
platform. Common markers throughout the CMYA5 gene regardless of their p-values are shown here.

Denotations:
1) rs3087813
2) rs11960229
3) rs16877060
4) rs6870619
5) rs6880680
6) rs3828611
7) rs1991483
8) rs1428227
9) rs12655366
10) rs259124
11) rs259127
12) rs259129
13) rs259130
14) rs12547828
15) rs1129770
16) rs66682
17) rs3749683
18) rs10043986
19) rs7343
20) rs16877214
21) rs735639
22) rs259067
23) rs259066
24) rs259053
25) rs4704591
26) rs430866
27) rs17471700
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LD Block Structures of Common Markers between GAIN & CATIE: NOS1AP

Figure 9. LD Block Structures of Common Markers between GAIN & CATIE: NOS1AP

rs164151

rs4657150

rs1337061

rs1337062

rs4656349

rs1123217

rs164151

rs4657150

rs1337061

rs1337062

2) GAIN

rs4656349

rs1123217

1) CATIE
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PTPN21

5’

rs2274736:
Coding Region
Nonsynonymous
change (Val ‐> Ala)
C to T transition
Allele frequency:
C = 0.354; T = 0.646

3’

rs2401751:
Coding Region
Nonsynonymous
change (Leu ‐> Phe)
C to T transition
Allele frequency:
C = 0.646; T = 0.354

rs10150311:
Intronic
T to C transition
Allele frequency:
C = 0.317; T = 0.683

Figure 10. SNP localization along the PTPN21 gene. Location of each investigated SNP within the PTPN21 gene with their
respective allelic frequencies.
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EML5

5’

3’

rs17260415:
Intronic
C to G transition
Allele frequency:
C = 0.72; G = 0.28

rs7147796:
Intronic
C/G
Allele frequency:
C = 0.469; G = 0.531

Figure 11. SNP localization along the EML5 gene. Location of each investigated SNP within the EML5 gene with their respective
allelic frequencies.
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CMYA5

5’

3’

rs3828611:
Coding Region
Nonsynonymous
change (His ‐> Gln)
C to G transition
Allele frequency:
C =0.942; G = 0.058

rs10043986:
Coding Region
Nonsynonymous
change (Pro ‐> Leu)
C to T transition
Allele frequency:
C =0.959; T = 0.041

rs4704591:
Untranslated
Region
G to C transition
Allele frequency:
C = 0.385; G = 0.615

Figure 12. SNP localization along the CMYA5 gene. Location of each investigated SNP within the CMYA5 gene with their
respective allelic frequencies.
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NOS1AP

5’

3’

rs1123217:
Intronic
G to C transition
Allele frequency:
C =0.03; G = 0.97

Figure 13. SNP localization along the NOS1AP gene. Location of each investigated SNP within the NOS1AP gene with their
respective allelic frequencies
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3.4. Statistical Results
Table 4 shows single-locus association results from the ISHDSF sample grouped by gene,
and Table 5 shows those from the ICCSS sample. No marker was shown to be statistically
significant (p <0.05) for ISHDSF and ICCSS samples. The lowest p-value achieved was 0.0883
with rs10043986 for the CMYA5 gene in the ICCSS sample, but it is not statistically significant.
Three markers, rs3828611, rs10043986, and rs4704591, of the CMYA5 gene were
additionally tested with the ITRIO sample. Marker rs4704591 from the CMYA5 gene was
statistically significant in this sample (p = 0.04479) (Table 8). When the three replication
samples (ICCSS + ISHDSF + ITRIO) are combined and analyzed, its significance improved (p =
0.00388), as alleles are in the same direction for the samples (Table 8 & 9). On the other hand,
the combined analysis of rs3828611 resulted in a less significant p-value, as the direction of the
allele was flipped for the ITRIO sample, indicated by the value of odds ratio (Table 9).
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Marker ID
Marker
Gene
Polymorphism
1
rs2274736
PTPN21
G/A
2
rs2401751
PTPN21
A/G
3
rs10150311 PTPN21
G/A
4
rs17260415 EML5
G/C
5
rs7147796
EML5
C/G
6
rs3828611
CMYA5
G/C
7
rs10043986 CMYA5
T/C
8
rs4704591
CMYA5
C/G
9
rs1123217
NOS1AP
G/C
MAF denotes minor allele frequency; OR denotes odds ratio.

Table 4. Single marker associations (p values) of the ISHDSF sample

MAF
0.355
0.349
0.314
0.282
0.472
0.061
0.123
0.376
0.055

p-value
0.8848
0.8108
0.8446
0.6766
0.44
0.3359
0.7467
0.0936
0.8657

OR
0.740 [0.451, 1.212]
0.775 [0.468, 1.283]
0.739 [0.451, 1.212]
0.686 [0.411, 1.142]
1.358 [0.865, 2.131]
1.111 [0.451, 2.741]
1
[0.554, 1.806]
0.659 [0.418, 1.037]
1
[0.351, 2.851]
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Marker ID
Marker
Gene
Polymorphism
1
rs2274736
PTPN21
G/A
2
rs2401751
PTPN21
A/G
3
rs10150311 PTPN21
G/A
4
rs17260415 EML5
G/C
5
rs7147796
EML5
C/G
6
rs3828611
CMYA5
G/C
7
rs10043986 CMYA5
T/C
8
rs4704591
CMYA5
C/G
9
rs1123217
NOS1AP
G/C
MAF denotes minor allele frequency; OR denotes odds ratio.

MAF
0.35
0.345
0.317
0.286
0.478
0.060
0.130
0.355
0.038

Table 5. Single marker associations (p values) of the ICCSS sample

p-value
0.52585
0.67394
0.57809
0.23790
0.6808
0.67949
0.08830
0.19820
0.73411

OR
0.936 [0.7911, 1.107]
0.9503 [0.804, 1.123]
0.9496 [0.8006, 1.126]
0.9952 [0.8349, 1.186]
1.044 [0.8895, 1.225]
1.059 [0.7579, 1.479]
0.8149 [0.6439, 1.031]
0.9008 [0.7632, 1.063]
0.8977 [0.5944, 1.356]
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Marker ID
1
2
3
4
5
6
7
8
9
MAF denotes minor allele frequency.

Marker
rs2274736
rs2401751
rs10150311
rs17260415
rs7147796
rs3828611
rs10043986
rs4704591
rs1123217

Gene
PTPN21
PTPN21
PTPN21
EML5
EML5
CMYA5
CMYA5
CMYA5
NOS1AP

Polymorphism
G/A
A/G
G/A
G/C
C/G
G/C
T/C
C/G
G/C

p-value
0.35410
0.23447
0.13893
0.19597
0.08274
0.87345
0.42478
0.00388
0.41842

Table 6. Single marker associations (p values) of the combined replication for all markers. For CMYA5 gene, ICCSS + ISHDSF
+ ITRIO; for all other genes, ICCSS + ISHDSF.
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Discovery 1
(GAIN -Caucasian)

Discovery 2
(CATIE - Caucasian)

Discovery Combined
(1+2)

Cases n = 1172
Controls n = 1378
Missing phenotype n = 51

Cases n = 492
Controls n = 523
Missing phenotype n = 0

Cases n = 1686
Controls n = 1901
Missing phenotype n = 51

Chr./Mb

SNP

Minor
Allele

SZ

CON

Allelic
P-value

SZ

CON

Allelic
P-value

SZ

CON

Allelic
P-value

5/79070418

rs3828611

G

0.074

0.058

0.02248

0.068

0.049

0.01704

0.074

0.056

0.00310

5/79131173

rs10043986

T

0.116

0.135

0.04148

0.098

0.139

0.02514

0.110

0.136

0.00126

5/79139227

rs4704591

C

0.359

0.408

0.00036

0.362

0.406

0.03813

0.360

0.408

0.00004

SZ and CON; allele frequency in schizophrenia and controls.
Table 7. CMYA5 Gene Combined Discovery Sample (GAIN & CATIE) Analyses.
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Replication 1 (ICCSS)

Replication 2
(ISHDSF)
Cases n = 522
Controls n = 869
MA MA P-value
SZ CON
N/A N/A 0.3359

Replication 3 (ITRIO)
Cases n = 216
Controls n = 372
MA
MA
P-value
SZ
CON
0.041 0.052 0.48179

Chr./Mb

SNP

5/79070418

rs3828611

Cases n = 657
Controls n = 411
MA
MA
P-value
SZ
CON
0.061 0.058 0.67949

5/79131173

rs10043986

0.119

0.142

0.08830

N/A

N/A

0.7467

0.094

0.010

0.79855

5/79139227

rs4704591

0.343

0.368

0.19820

N/A

N/A

0.0936

0.346

0.419

0.04479

Replications
Combined
(1+2 +3)
Cases n = 1395
Controls n = 1652
MA
MA
PSZ
CON
value
0.058 0.057 0.8734
5
0.119 0.142 0.4247
8
0.343 0.367 0.0038
8

MA SZ and MA CON; minor allele frequency in schizophrenia and controls.
Table 8. CMYA5 Gene Combined Replication Sample (ICCSS + ISHDSF + ITRIO) Analyses. Single marker associations were
calculated for ICCSS, ISHDSF, and ITRIO samples respectively and also for the combined samples (ICCSS + ISHDSF + ITRIO).
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Marker
ID

Marker

GAIN OR
CATIE OR
ICCSS OR
0.8385
0.8368
0.936
1 rs2274736 [0.7455, 0.9431] [0.7222, 0.9696]
[0.7911, 1.107]
0.8256
0.8157
0.9503
2 rs2401751 [0.7335, 0.9292] [0.7013, 0.9487]
[0.804, 1.123]
0.8341
0.8811
0.9496
3 rs10150311 [0.7389, 0.9416] [0.7588, 1.0232]
[0.8006, 1.126]
0.859
0.8195
0.9952
4 rs17260415 [0.757, 0.9747]
[0.692, 0.9705]
[0.8349, 1.186]
1.1179
1.0302
1.044
5 rs7147796 [1, 1.2498]
[0.8866, 1.197]
[0.8895, 1.225]
1.3121
1.4255
1.059
6 rs3828611 [1.0476, 1.6434] [0.9796, 2.0743]
[0.7579, 1.479]
0.8435
0.6718
0.8149
[0.6439, 1.031]
7 rs10043986 [0.7133, 0.9973] [0.5107, 0.8835]
0.813
0.8273
0.9008
[0.7632, 1.063]
8 rs4704591 [0.7255, 0.9111] [0.6915, 0.9898]
0.593
0.8293
0.8977
[0.5944, 1.356]
9 rs1123217 [0.4458, 0.7889] [0.6408, 1.073]
OR denotes odds ratio. Brackets indicate 95% confidence intervals for the OR.

TRIADS OR
N/A
N/A
N/A
N/A
N/A
0.7778
[0.3868, 1.564]
0.9355
[0.5637, 1.552]
0.747
[0.5553, 1.005]
N/A

ISHDSF OR
0.7396
[0.4514, 1.212]
0.775
[0.4681, 1.283]
0.7393
[0.4507, 1.212]
0.6855
[0.4114, 1.142]
1.358
[0.8649, 2.131]
1.111
[0.4505, 2.741]
1
[0.5538, 1.806]
0.6585
[0.4182, 1.037]
1
[0.3508, 2.851]

Table 9. Odds Ratio Analyses of All Samples. All samples were analyzed using UNPHASED v.3.1.
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CHAPTER 4: DISCUSSION
The SZ research community has produced a plethora of research data involving a large
number of candidate genes and various ethnic groups as samples. As this trend continues, it has
become increasingly important to devise methods to effectively and systematically integrate
accumulated data in order to select a list of “prioritized” candidate genes (Le-Niculescu et al.,
2007). Publicly available genome-wide association studies such as GAIN and CATIE introduced
in this study not only cover markers across the genome, but also provide information for a large
number of samples. The current study takes an approach of selecting candidate genes by relying
on statistical evidence from not just one set of GWAS data, but on two. This study design
assumed the hypothesis that p-values from GWAS datasets suggest an increased likelihood of
such markers being replicated in other populations. Although each of these large GWAS datasets
is able to provide immensely useful information on its own, a successful integration of the
datasets increases the chance of selecting promising candidate genes for further examinations by
basing the selection upon evidence from independent samples. This is likely to improve the
reliability for candidate selection.
From the results of the current study, we successfully replicated one of the 9 markers
tested, or one of 4 candidate genes. Our performance is slightly better than random selection.
However, it is difficult to attribute the better performance strictly to statistical evidence (pvalue) from GWAS datasets, because, judging from the p-values of the markers selected from
both GAIN and CATIE, rs4704591, the one marker successfully confirmed, is not the best one
among the 9 selected markers (see data in Table 3).
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Although the correctness of our hypothesis remains uncertain, the scarcity of statistically
significant findings from the current study may be partially accounted for by the lack of power
due to small replication sample sizes. A review of odds ratios (Table 9) reveals that for some of
the markers genotyped, the sample sizes were not efficient to detect their effects. In addition to
the statistical significance found with rs4704591 (CMYA5 gene) in the ITRIO sample, modest
effects observed in other samples for the same marker were seen to be in the same direction on
the same allele, which led to the p-value of the combined analyses of all replication samples to
be relatively small (p-value = 0.00388). Thus, more replications are needed to verify CMYA5 as
a true susceptibility gene for Schizophrenia and also for other genes in the study. If additional
replications still produce negative associations of such genes with SZ, such reports provide
useful information so that the next generation of research studies can be appropriately focused.
Schizophrenia is thought to be caused by a large number of contributing loci with subtle
effects, interactions (gene-gene, gene-environment, intralocus), complex single locus effects, or
parent-of-origin or epigenetic effects (The Psychiatric GWAS Consortium Steering Committee,
2009). This fact points us to areas in which future studies can improve on. One could argue that
selecting significant p-values from a simple additive genetics model of GWAS may not be
sufficient for discovering candidate genes and SNPs for SZ, which is thought to not conform to
this model. In addition, whereas GWAS assess only a subset of genetic variants (SNPs and
CNVs), there are many other types of genetic variants that may be important and that could be
systematically incorporated into candidate selection. Another possible area of error may be found
in analyzing the combined CATIE and GAIN datasets. A direct overlap between different
platforms is often modest at best, and these platforms must be made comparable in terms of
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SNPs included, subjects, and other factors of bias such as population stratification, cryptic
relatedness or genotyping batch effects (The Psychiatric GWAS Consortium Steering Committee,
2009). In the current study, efforts were made to eliminate ethnic heterogeneity of subjects
present in the CATIE study that is not comparable with the GAIN study by employing only
Caucasian samples for our analyses. However, other factors of platform compatibility were not
resolved, and future studies may benefit from considering the issue.
Out of the four genes investigated for association with schizophrenia in the current study,
a promising result emerged from the CMYA5 gene. As for the markers that failed to show
significance, the knowledge of what a disorder is not, has its value in appropriately focusing the
next generation of research. The positive association found with CMYA5 is exciting, as the
discovery was made with the presence of a compelling association without an obvious biological
function of the gene in the nervous system. CMYA5 being a binding partner for dysbindin in
muscles sheds light on the effects of glutamatergic neurotransmission on the pathophysiology of
schizophrenia in which dysbindin is involved. Glutamatergic neurons innervate the cortex,
limbic regions, and striatum as a part of excitatory afferent and efferent systems. A family of
glutamate-gated ion channels that depolarize neurons mediate the postsynaptic actions of
glutamate. Psychotomimetics such as phencyclidine act on one of these receptors, the N-methylD-asparate (NMDA) receptor, and reproduce schizophrenic symptoms in normal individuals. It
has been suspected that glutamatergic dysfunction is especially relevant to schizophrenia forms
in which negative symptoms, cognitive deficits, and deterioration are prominent. In addition,
drugs that enhance NMDA-receptor functions reduce such symptoms in chronic schizophrenia
patients (Coyle, 1996). The association made with the CMYA5 gene gives future researchers a
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starting point to determine how variations in related glutamatergic pathways or genetic regions
affect vulnerability to schizophrenia. Currently, our laboratory is collaborating with other
institutions in order to replicate our results on the CMYA5 gene in other samples. Long-term
goals of the current study may enable clinicians to prevent schizophrenia, or to identify cases
earlier for more efficacious treatments which may lead to decreased mortality.
For the GWAS data based on individual genotyping thus far reported, the total combined
sample sizes are still small (fewer than 1500 cases), and the power to identify small genetic
effects is limited (Williams et al., 2009). The current study made an improvement on previous
GWAS-based studies by increasing the discovery sample size to better approximate marker
significances. Although it is inconclusive how beneficial this approach was in the current study,
as a result, we identified CMYA5 to be associated with schizophrenia in our Irish samples. The
finding provides a cause for optimism that larger scale of future studies will be able to identify
additional loci associated with schizophrenia.
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